Focal therapy for prostate cancer: Fact or fiction?

Urologic Oncology: Seminars and Original Investigations

Volumn 28, Issue 5, 2010, Pages 550-556

  Lecornet, Emilie ^a,b   Moore, Caroline ^a   Ahmed, Hashim Uddin ^a   Emberton, Mark ^a,c  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b Service d'urologie   (France)

^c UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

Author keywords

Cryotherapy; Focal therapy; HIFU; Photodynamic therapy; Prostate cancer

Indexed keywords

CANCER RADIOTHERAPY; HIGH INTENSITY FOCUSED ULTRASOUND; HUMAN; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; REVIEW; UNITED KINGDOM;

CRYOTHERAPY; HUMANS; MALE; PHOTOCHEMOTHERAPY; PROSTATIC NEOPLASMS; ULTRASONIC THERAPY;

EID: 77956282899     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urolonc.2010.08.004     Document Type: Review

References (48)

1. Bill-Axelson A., Holmberg L., Ruutu M. Radical prostatectomy vs. watchful waiting in early prostate cancer. N Engl J Med 2005, 352:1977-1984.
2. Polascik T.J., Mouraviev V. Focal therapy for prostate cancer is a reasonable treatment option in properly selected patients. Urology 2009, 74:726-730.
3. Parker C., Muston D., Melia J., et al. A model of the natural history of screen-detected prostate cancer, and the effect of radical treatment on overall survival. Br J Cancer 2006, 94:1361-1368.
4. Hu J.C., Hevelone N.D., Ferreira M.D., et al. Patterns of care for radical prostatectomy in the United States from 2003 to 2005. J Urol 2008, 180:1969-1974.
5. Galbraith M.E., Ramirez J.M., Pedro L.W. Quality of life, health outcomes, and identity for patients with prostate cancer in five different treatment groups. Oncol Nurs Forum 2001, 28:551-560.
6. Litwin M.S., Lubeck D.P., Spitalny G.M., et al. Mental health in men treated for early stage prostate carcinoma: A post-treatment, longitudinal quality of life analysis from the Cancer of the Prostate Strategic Urologic Research Endeavor. Cancer 2002, 95:54-60.
7. Dale W., Bilir P., Han M., et al. The role of anxiety in prostate carcinoma: A structured review of the literature. Cancer 2005, 104:467-478.
8. Pickles T., Ruether J.D., Weir L., et al. Psychosocial barriers to active surveillance for the management of early prostate cancer and a strategy for increased acceptance. BJU Int 2007, 100:544-551.
9. Latini D.M., Hart S.L., Knight S.J., et al. The relationship between anxiety and time to treatment for patients with prostate cancer on surveillance. J Urol 2007, 178(3 Pt 1):826-831. , Discussion 831-2.
10. Burnet K.L., Parker C., Dearnaley D., et al. Does active surveillance for men with localized prostate cancer carry psychological morbidity?. BJU Int 2007, 100:540-543.
11. Black P. There is no role for focal therapy in prostate cancer. Can Urol Assoc J 2009, 3:331-332.
12. Berglund R.K., Masterson T.A., Vora K.C., et al. Pathologic upgrading and up staging with immediate repeat biopsy in patients eligible for active surveillance. J Urol 2008, 180:1964-1967. , Discussion 1967-8.
13. Johansson J.E., Andrén O., Andersson S.O., et al. Natural history of early, localized prostate cancer. JAMA 2004, 291:2713-2719.
14. Sartor A.O., Hricak H., Wheeler T.M., et al. Evaluating localized prostate cancer and identifying candidates for focal therapy. Urology 2008, 72(6 Suppl):S12-S24.
15. Onik G., Barzell W. Transperineal 3D mapping biopsy of the prostate: An essential tool in selecting patients for focal prostate cancer therapy. Urol Oncol 2008, 26:506-510.
16. Villers A., Lemaitre L., Haffner J., et al. Current status of MRI for the diagnosis, staging and prognosis of prostate cancer: Implications for focal therapy and active surveillance. Curr Opin Urol 2009, 19:274-282.
17. Umbehr M., Bachmann L.M., Held U., et al. Combined magnetic resonance imaging and magnetic resonance spectroscopy imaging in the diagnosis of prostate cancer: A systematic review and meta-analysis. Eur Urol 2009, 55:575-590.
18. DiBiase S.J., Hosseinzadeh K., Gullapalli R.P., et al. Magnetic resonance spectroscopic imaging-guided brachytherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2002, 52:429-438.
19. Langenhuijsen J.F., Broers E.M., Vergunst H. Cryosurgery for prostate cancer: An update on clinical results of modern cryotechnology. Eur Urol 2009, 55:76-86.
20. Onik G. Image-guided prostate cryosurgery: State of the art. Cancer Control 2001, 8:522-531.
21. Cohen J.K., Miller R.J., Ahmed S., et al. Ten-year biochemical disease control for patients with prostate cancer treated with cryosurgery as primary therapy. Urology 2008, 71:515-518.
22. Ahmed H.U., Moore C., Emberton M. Minimally-invasive technologies in uro-oncology: The role of cryotherapy, HIFU and photodynamic therapy in whole gland and focal therapy of localized prostate cancer. Surg Oncol 2009, 18:219-232.
23. El Hayek O.R., Alfer W., Reggio E., et al. Prostate cryoablation: Prospective analysis comparing high- and low-risk prostate cancer outcomes. Urol Int 2008, 81:186-190.
24. Jones J.S., Rewcastle J.C., Donnelly B.J., et al. Whole gland primary prostate cryoablation: Initial results from the cryo on-line data registry. J Urol 2008, 180:554-558.
25. Onik G. The male lumpectomy: Rationale for a cancer targeted approach for prostate cryoablation. A review. Technol Cancer Res Treat 2004, 3:365-370.
26. Onik G., Vaughan D., Lotenfoe R., et al. The "male lumpectomy": Focal therapy for prostate cancer using cryoablation results in 48 patients with at least 2-year follow-up. Urol Oncol 2008, 26:500-505.
27. Onik G., Vaughan D., Lotenfoe R., et al. "Male lumpectomy": Focal therapy for prostate cancer using cryoablation. Urology 2007, 70(6 Suppl):16-21.
28. Onik G. Focal Therapy for Prostate Cancer: 120 Patients with up to 12-year follow-up. Proceedings of the SIR Annual Scientific Meeting, San Diego, California, 2009; [Abstract SS08e].
29. Lambert E.H., Bolte K., Masson P., et al. Focal cryosurgery: Encouraging health outcomes for unifocal prostate cancer. Urology 2007, 69:1117-1120.
30. Bahn DK, Silverman P, Lee F Sr, et al. Focal prostate cryoablation: Initial results show cancer control and potency preservation. J Endourol 206;20:688-92.
31. Onik G., Narayan P., Vaughan D., et al. Focal "nerve-sparing" cryosurgery for treatment of primary prostate cancer: A new approach to preserving potency. Urology 2002, 60:109-114.
32. Ellis D.S., Manny T.B., Rewcastle J.C. Focal cryosurgery followed by penile rehabilitation as primary treatment for localized prostate cancer: Initial results. Urology 2007, 70(6 Suppl):9-15.
33. Ellis D.S., Manny T.B., Rewcastle J.C. Cryoablation as primary treatment for localized prostate cancer followed by penile rehabilitation. Urology 2007, 69:306-310.
34. Dhar N, Scionti SM, Lugnani F. Focal/partial gland prostate cryoablation: Results of 795 patients from multiple centers tracked with the COLD registry. AUA 2009 [Abstract].
35. Ahmed H.U., Zacharakis E., Dudderidge T., et al. High-intensity-focused ultrasound in the treatment of primary prostate cancer: The first UK series. Br J Cancer 2009, 101:19-26.
36. Challacombe B.J., Murphy D.G., Zakri R., et al. High-intensity focused ultrasound for localized prostate cancer: Initial experience with a 2-year follow-up. BJU Int 2009, 104:200-204.
37. Blana A., Murat F.J., Walter B., et al. First analysis of the long-term results with transrectal HIFU in patients with localized prostate cancer. Eur Urol 2008, 53:1194-1201.
38. Muto S., Yoshii T., Saito K., et al. Focal therapy with high-intensity-focused ultrasound in the treatment of localized prostate cancer. Jpn J Clin Oncol 2008, 38:192-199.
39. Barret E PD, Cathelineau X, Roset F, et al. Focal therapy with HIFU for prostate cancer in elderly: Feasibility study with 10 years follow-up. Proceedings of the 2nd International Workshop on Focal therapy and Imaging in prostate and kidney cancer. Amsterdam, The Netherlands, June 2009.
40. Ahmed HU, Sahu M, Govindaraju SK, et al. High Intensity Focused Ultrasound (HIFU) hemiablation trial in localised unilateral prostate cancer: Interim results. Presented at the EAU Congress in Stockholm, Sweden, March 2009.
41. Sahu M, Ahmed HU, Kumaar S, et al. A Phase II Trial assessing the role of Focal Ablation using HIFU in Localised Prostate Cancer: interim results. Proceedings of the 2nd International Workshop on Focal therapy and imaging in prostate and kidney cancer. Amsterdam, The Netherlands, June 2009. Abstract P-64.
42. Sahu M, Ahmed HU, Kumaar S, et al. A Phase II Trial assessing the role of Focal Ablation using HIFU in Localised Prostate Cancer: interim results. Proceedings of the 2nd International Workshop on Focal therapy and imaging in prostate and kidney cancer. Amsterdam, The Netherlands, June 2009. Abstract P-65.
43. Windahl T., Andersson S.O., Lofgren L. Photodynamic therapy of localized prostatic cancer. Lancet 1990, 336:1139.
44. Nathan T.R., Whitelaw D.E., Chang S.C., et al. Photodynamic therapy for prostate cancer recurrence after radiotherapy: A phase I study. J Urol 2002, 168(4 Pt 1):1427-1432.
45. Moore C.M., Nathan T.R., Lees W.R., et al. Photodynamic therapy using meso tetra hydroxy phenyl chlorine (mTHPC) in early prostate cancer. Lasers Surg Med 2006, 38:356-363.
46. Trachtenberg J., Weersink R.A., Davidson S.R., et al. Vascular-targeted photodynamic therapy (padoporfin, WST09) for recurrent prostate cancer after failure of external beam radiotherapy: A study of escalating light doses. BJU Int 2008, 102:556-562.
47. Trachtenberg J., Bogaards A., Weersink R.A., et al. Vascular targeted photodynamic therapy with palladium-bacteriopheophorbide photosensitizer for recurrent prostate cancer following definitive radiation therapy: Assessment of safety and treatment response. J Urol 2007, 178:1974-1979. , Discussion 1979.
48. Haider M.A., Davidson S.R., Kale A.V., et al. Prostate gland: MR imaging appearance after vascular targeted photodynamic therapy with palladium-bacteriopheophorbide. Radiology 2007, 244:196-204.